Latest 10-K annual reports

USA Rare Earth reported minimal 2025 revenue, a $298.5 million net loss, closed key acquisitions, commissioned initial U.S. magnet capacity, and signed a $1.6 billion U.S. government LOI while raising $1.5 billion in January 2026.

Aura Biosciences reports a wider 2025 net loss, substantial doubt about going concern, active late‑stage bel-sar program under SPA, and recent/warranted financings to extend runway.

Eikon Therapeutics reported a larger 2025 net loss while advancing its oncology pipeline, closing a $349M IPO in February 2026 and guiding cash runway into 2H 2027 despite a disclosed material weakness and a license dispute.

SportsQuest reported no revenue, a $121,640 net loss, $259 year-end cash, and a working capital deficit while relying on convertible notes to fund operations.

Neumora outlined multiple 2026 readouts, detailed loan and ATM financing activity, and reported a $236.9M 2025 net loss with $182.5M in year-end cash as it advances MDD, Alzheimer’s agitation, schizophrenia and obesity programs.

CytoSorbents grew 2025 revenue 4% and improved margins but flagged going concern risks, Nasdaq noncompliance, and a reset FDA path for DrugSorb-ATR after a 2025 De Novo denial.

PMGC Holdings reported $0.59M in first-year operating revenue and a $7.75M net loss, executed dilutive financings backed by pledged subsidiaries, and plans to advance lead biotech asset EL-22 toward a U.S. IND in 2026.

Greenpro Capital’s 2025 revenue fell 41% and net loss deepened to $3.0M, as auditors raised substantial doubt about its ability to continue as a going concern and the company moved to issue 8.5M shares for a Forekast stake.

Unicycive’s 10-K details a manufacturing-related FDA delay for oxylanthanum carbonate, a resubmitted NDA with a June 29, 2026 PDUFA, strengthened cash via ATM offerings, and new shareholder litigation.

AIxCrypto Holdings reported a $17.0M 2025 net loss, rebranded from Qualigen, raised $41M, built a $10.3M crypto treasury, and narrowed its strategy to real‑world asset tokenization and embodied AI while warning of going concern risks and heavy dilution.

American Picture House Corporation’s 2025 10-K shows sharply higher revenue, a smaller net loss, new revenue waterfalls on released films, and fresh financing lines, but flags going concern risks and potential dilution.

CitroTech Inc. reported 2025 revenue up 195% to $2.38M, heavy stock-based charges driving a $36.8M net loss, new NYSE listing, and multiple financings to fund growth through 2026.

HyOrc posted sharply lower 2025 revenue amid a plant shutdown and legal dispute, added methanol JV and project agreements, and flagged going-concern and funding needs.

Perimeter Acquisition Corp. I filed its 2025 Form 10-K, detailing $247.75 million held in trust, no target selected yet, and a defense-focused deal mandate with a 24‑month completion window.

Picard Medical posted a larger 2025 net loss amid modest revenue growth, completed a $19.6M IPO and issued $15M of senior secured notes with attached warrants as auditors flagged going-concern risk.

Soluna reported lower 2025 revenue and a wider net loss but ended the year with $76.4M cash, secured new project financing, advanced key data centers, and added a $250M equity facility in March 2026.

AIM ImmunoTech's 2025 annual report highlights a strategic pivot to late-stage pancreatic cancer for Ampligen, despite ongoing financial losses and NYSE American delisting concerns.

Space Asset Acquisition Corp. (SAAQ) filed its annual 10-K, outlining its blank check company structure, IPO details, and strategy to acquire a business in the global space economy.

Immix Biopharma, Inc. filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the auditor report date, while revealing significant capital raises and increased liquidity despite growing net losses.

Gesher Acquisition Corp. II, a SPAC, reported a net income of $3.47 million for 2025, driven by interest income, but faces substantial doubt about its ability to continue as a going concern without completing a business combination by December 2026.

K&F Growth Acquisition Corp. II, a SPAC, reported a net income of $10.2 million for 2025, primarily from trust account interest, but faces substantial doubt about its ability to continue as a going concern without a business combination by November 2026.

Enveric Biosciences, a biotechnology company, reported substantial doubt about its ability to continue as a going concern despite recent capital raises, as it focuses on preclinical development of its lead neuroplastogen candidate, EB-003.

SKYX Platforms Corp. filed an amended annual report for fiscal year 2025, primarily to correct an auditor report date, while highlighting ongoing liquidity challenges and recent capital raises.

Fusemachines Inc. reported a significantly reduced net loss for 2025 following a business combination, but faces a Nasdaq listing compliance issue and ongoing going concern doubts.

Utah Medical Products Inc. reported a decline in 2025 revenues and net income, impacted by lost OEM sales and Filshie Clip litigation, despite maintaining strong cash reserves.

DICK'S Sporting Goods reports a 28.1% net sales increase to $17.22 billion in fiscal 2025, driven by the Foot Locker acquisition and 4.5% comparable sales growth in its core business, despite a significant drop in net income due to acquisition-related costs.

Air Industries Group reported a net loss of $1.3 million in 2025, faces substantial doubt about its ability to continue as a going concern, and plans a highly dilutive merger with Tenax Aerospace Acquisition.

Spartacus Acquisition Corp. II, a SPAC, outlines its post-IPO structure, financial position, and search for a business combination in the TMT sector.

Daedalus Special Acquisition Corp. successfully completed its $250 million IPO and private placement, positioning itself to acquire a leading consumer AI company.

SIM Acquisition Corp. I reports a strategic pivot to U.S. industrial and tech sectors, new leadership, and a fee reduction agreement, while acknowledging substantial doubt about its ability to continue as a going concern.